SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: aknahow who wrote (5165)12/20/1997 8:27:00 AM
From: Robert K.  Read Replies (1) | Respond to of 17367
 
130flex has something to do with recent discussions with fda and uk(fda)I think also the rapid accrual means they might go for a even larger sample for more definative results. CF site was one ,soon to be two.Remember cf is a "test the waters" type trial as was meningo p1/2. If it starts to show results then accrual will accelerate IMO.



To: aknahow who wrote (5165)12/20/1997 8:48:00 AM
From: William L. Molair II  Read Replies (1) | Respond to of 17367
 
Options are available for XOMA?